Regulatory considerations for paediatric drug evaluation in China
The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in l...
Saved in:
Main Authors: | Hao Zhang (Author), Wei Zhao (Author), Qiang Li (Author), Zhi-Min Yang (Author), Ying Geng (Author), Yan-Zhe Sun (Author), Yong-Lin Jiang (Author), Li-Qing Wang (Author), Yue-E Wu (Author) |
---|---|
Format: | Book |
Published: |
BMJ Publishing Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Paediatric drugs trials in China
by: Wei Zhao, et al.
Published: (2020) -
FDA regulatory considerations for oncology drug development
by: Hanlim Moon, et al.
Published: (2024) -
Practical, regulatory and clinical considerations for development of inhalation drug products
by: Shuguang Hou, et al.
Published: (2015) -
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
by: Yang Liu, et al.
Published: (2022) -
Evolving drug regulatory landscape in China: A clinical pharmacology perspective
by: Weifeng Tang, et al.
Published: (2021)